Biologically Targeted Therapeutics

  • Ernest C. Borden

Part of the Current Clinical Oncology book series (CCO)

Table of contents

  1. Front Matter
    Pages i-xvi
  2. Perspective on the Clinical Disease

    1. Front Matter
      Pages 1-1
    2. Philip L. Bailin, Jon S. Meine, Christine Poblete-Lopez
      Pages 3-38
    3. Hamed Daw, Thomas Olencki
      Pages 73-92
  3. Biological and Targeted Therapeutics

    1. Front Matter
      Pages 93-93
    2. Peter A. Cohen, Suyu Shu, James H. Finke
      Pages 95-139
    3. Stanley P. L. Leong, Suyu Shu
      Pages 141-156
    4. Paul B. Chapman, Jedd D. Wolchok
      Pages 157-182
    5. James W. Mier, Michael B. Atkins
      Pages 183-219
    6. Ronald M. Bukowski, Charles Tannenbaum
      Pages 221-234
    7. Ernest C. Borden
      Pages 235-258
    8. Lawrence E. Flaherty, Philip Agop Philip
      Pages 259-285
    9. Ruth Halaban, Maria C. von Willebrand
      Pages 287-323
    10. Bela Anand-Apte, Paul L. Fox
      Pages 325-360
    11. Vann P. Parker
      Pages 361-377
  4. Back Matter
    Pages 379-389

About this book


Substantial progress in the effective prevention and treatment of primary and recurrent melanomas is now being regularly achieved using therapeutic proteins and cells. In Melanoma: Biologically Targeted Therapeutics, Ernest C. Borden, MD, has assembled a multidisciplinary team of established and emerging leaders to detail the clinical problems and factors influencing the therapeutic deployment of these biologicals. Throughout, the focus is on providing the rationale and background by which the many promising biologically targeted therapies are translated via clinical trials into effective new therapies. Among the interventional agents treated are cytokines, monoclonal antibodies, targeted inhibitors, cellular therapies, and angiogenesis inhibitors. Special attention is given to adjuvant therapies for melanoma in patients staged as being at high risk for recurrence. These therapies include interferons, vaccines aimed at stimulating T cell response, and therapies targeted at abnormal melanoma cell proliferative signaling and angiogenesis inhibitors. Among the cutting-edge therapies discussed are novel cytokines that influence dendritic NK and T cell function, an allogenic cellular extract vaccine, and new targets (NF-kB and IL-8) for antiangiogenesis therapies.
State-of-the-art and forward looking, Melanoma: Biologically Targeted Therapeutics critically evaluates the biological, cellular, and targeted therapies that are already reducing mortality from primary melanomas, and are expected increasingly to continue so for the foreseeable future.


Staging angiogenesis metastatic disease surgery tumor growth

Editors and affiliations

  • Ernest C. Borden
    • 1
  1. 1.Center for Cancer Drug Discovery and Development, Taussig Cancer CenterThe Cleveland Clinic FoundationClevelandUSA

Bibliographic information

Industry Sectors
Health & Hospitals
Oncology & Hematology